is.......................Broke and can't be fixed.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
3/17/2011
(DEPO) DEPO (Caris Price Target Change) Gets Gralise back with a $40M cherry on top – maintain 1*/Buy, raising PT to $17
18 48 99
There is blood in the water. Dow down nearly 300.
SHhhhhhhhhhhhh
Funny you should say that....
It's five o'clock somewhere just played on my pandora....Hmmmn
Perhaps I'll get a shine on.
I'm looking forward to this weekend.
I got a cool mill that says nobody beats me this weekend!
Any takers?
I woke up around 2 this morning. Turned on the tv and was watching the news. Unbelievable to see a tsunami LIVE.
It was so humbling, so sad.
Visteon Announces 2010 Financial Results
VAN BUREN TOWNSHIP, Mich., March 9, 2011 /PRNewswire via COMTEX/ --
Full Year 2010 Highlights
Product sales of $7.32 billion, up $903 million from prior year
Net income of $1.03 billion, including $933 million of net reorganization gains
Adjusted EBITDA of $614 million, up $160 million year-over-year
Cash generated by operating activities of $174 million, up $33 million from 2009
Year-end cash balances of $979 million; total debt of $561 million
Common stock listed on NYSE; trading since Jan. 10, 2011 (symbol: VC)
Is your real name Steve Austin?
How many wives do you have?
red, if you're comin up here, can I house sit for ya?
Thank you much appreciated.
Actually, I was wondering if the results for each week were posted.
The rankings for the week not the combined rankings for all the weeks.
Thanks.....
BnB,
How's this for me acting like a little whiner.......Now I like the layout the way it is. Guess I just had to get used to it.
Do you show the weekly rankings anywhere?
The only ticket I ever got in my life that pissed me off was this past september. I was driving from NC to PA after going down to clean up after a hurricane. On the way back it was 5 in the morning in Deleware and I got pulled over when the speed limit changed from 55 to 45 to 35. She said I was doing 51 in a 35. No warning, no reduction in speed. Wrote me up for the whole thing and then gave me the "I'm just doing my job" speech.
Just curious, do you think someone who carries a badge should get no tickets, same tickets as everyone else or a ticket with a higher price tag because they should be held to a higher standard?
I've heard many people present many arguments for all three.
I need to start picking cars that finish higher than the ones I don't pick.
Kobalt Tools 400
11, 18, 22
Depomed has added a news release to its Investor Relations website.
Title: Depomed Reports Fourth Quarter and Year-End 2010 Financial Results
Date(s): 3-Mar-2011 4:05 PM
For a complete listing of our news releases, please click here
MENLO PARK, Calif., Mar 3, 2011 (GlobeNewswire via COMTEX) --
Depomed, Inc. (Nasdaq:DEPO) today reported financial results for the fourth quarter and year ended December 31, 2010.
"We are pleased to report a profitable year and our third consecutive profitable quarter," said Carl A. Pelzel, president and chief executive officer of Depomed. "Our excellent financial performance and business progress in 2010, as well as the $48 million milestone payment from Abbott Products received last week, provide us with substantial resources to pursue our plan to achieve sustainable profitability from recurring operating revenue from our own specialty pharmaceutical business. Meanwhile, we look forward to the results of Serada's Breeze 3 trial later this year, as enrollment has just concluded," Mr. Pelzel added.
Fourth Quarter 2010 and Recent Highlights
-- Presentations of Breeze 1 and 2 clinical data at the North American
Menopause Society annual meeting (October 2010);
-- Awarded a second grant by The Michael J. Fox Foundation to support
clinical development of DM-1992 for Parkinson's disease (October 2010);
-- Receipt of a $5.0 million milestone payment from Janssen Pharmaceutica
for delivery of formulation (October 2010, recognized as revenue during
the third quarter of 2010);
-- Receipt of a $2.5 million development milestone payment pursuant to the
agreement with Merck (October 2010, recognized as revenue during the
fourth quarter of 2010);
-- Availability and re-launch of Glumetza 500mg tablets (January 2011);
-- Achievement of a $3.0 million Glumetza sales milestone payment from
Santarus, Inc. to be paid in March 2011 (January 2011);
-- US FDA approval of Gralise (gabapentin) once-daily tablets for treatment
of post-herpetic neuralgia (January 2011);
-- Results of the Phase 1 trial of twice-daily formulation of DM-1992 in
Parkinson's patients (February 2011);
-- Receipt of a $48.0 million milestone payment from Abbott Products on FDA
approval of Gralise (February 2011);
-- Completion of enrollment in Breeze 3, our pivotal Phase 3 trial
evaluating Serada for menopausal hot flashes (March 2011).
Depomed Fourth Quarter and Full-Year 2010 Financial Highlights
Total revenue for the fourth quarter of 2010 was $20.9 million compared to $13.2 million in the fourth quarter of 2009. The increase in revenue in the fourth quarter of 2010 was the result of recognition of the $2.5 million Merck milestone, an increase in Glumetza product sales and revenues related to our collaborative arrangements with Janssen and Covidien.
Total revenue for the year-ended December 31, 2010 was $80.8 million compared to $57.7 million for the year-ended December 31, 2009. The increase in revenue in 2010 was the result of increases in Glumetza product sales and revenues related to our collaborative arrangements with Abbott Products, Janssen and Covidien.
Glumetza product sales were $11.5 million and $45.5 million for the fourth quarter and year-ended December 31, 2010, as compared to $9.8 million and $34.6 million for the corresponding periods in 2009.
Operating expenses were $18.5 million for the fourth quarter of 2010 and included $7.7 million in promotion fee expense related to the Company's promotion agreement with Santarus, compared with operating expenses of $15.3 million for the fourth quarter of 2009, which included $6.6 million in promotion fee expense.
Operating expenses were $69.0 million for year ended December 31, 2010 and included $31.4 million in promotion fee expense, compared with operating expenses of $74.5 million for the year ended December 31, 2009, which included $23.6 million in promotion fee expense. The decrease in operating expenses for the year ended December 31, 2010 was primarily driven by the completion of the Phase 3 clinical trial for Gralise and completion of the first two Phase 3 clinical trials for Serada during 2009.
Net income during the fourth quarter of 2010 was $1.7 million, or $0.03 cents per share, compared to a net loss during the fourth quarter of 2009 of $3.6 million, or $0.07 cents per share.
Net income for the year ended December 31, 2010 was $3.9 million, or $0.07 cents per share, compared to a net loss during the year ended December 31, 2009 of $22.0 million, or $0.43 cents per share.
Cash, cash equivalents and marketable securities were $76.9 million as of December 31, 2010 compared to $81.8 million as of December 31, 2009. Cash, cash equivalents and marketable securities at December 31, 2010 does not include the $48.0 million milestone payment from Abbott Products that we received in February 2011.
Conference Call
Depomed will host a conference call today, Thursday, March 3, beginning at 5:00 p.m. ET, 2:00 p.m. PT to discuss its results. The conference call will be available via a live webcast on the investor relations section of Depomed's website at http://www.depomed.com. Access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.
About Depomed
Depomed, Inc. is a specialty pharmaceutical company with one approved product on the market and has developed another approved product. Gralise(TM) (gabapentin) is a once-daily treatment approved in the United States for management of post-herpetic neuralgia (PHN) and has been licensed to Abbott Products, Inc. Glumetza(R) (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and promoted by Santarus, Inc. in the United States. The company also has a robust pipeline including one in Phase 3 clinical development, and other product candidates in its early stage pipeline. Product candidate Serada(R) is in Phase 3 clinical development for menopausal hot flashes. Depomed formulates its products and product candidates with its proven, proprietary Acuform(R) drug delivery technology, which is designed to improve existing oral medications, allowing for controlled release of medications to the upper gastrointestinal tract when dosed with food. Additional information about Depomed may be found on its website, http://www.depomed.com.
DEPO
Depomed Reports Fourth Quarter and Year-End 2010 Financial Results
MENLO PARK, Calif., March 3, 2011 — Depomed, Inc. (NASDAQ: DEPO) today reported financial results for the fourth quarter and year ended December 31, 2010.
“We are pleased to report a profitable year and our third consecutive profitable quarter,” said Carl A. Pelzel, president and chief executive officer of Depomed. “Our excellent financial performance and business progress in 2010, as well as the $48 million milestone payment from Abbott Products received last week, provide us with substantial resources to pursue our plan to achieve sustainable profitability from recurring operating revenue from our own specialty pharmaceutical business. Meanwhile, we look forward to the results of Serada’s Breeze 3 trial later this year, as enrollment has just concluded,” Mr. Pelzel added.
Fourth Quarter 2010 and Recent Highlights
· Presentations of Breeze 1 and 2 clinical data at the North American Menopause Society annual meeting (October 2010);
· Awarded a second grant by The Michael J. Fox Foundation to support clinical development of DM-1992 for Parkinson’s disease (October 2010);
· Receipt of a $5.0 million milestone payment from Janssen Pharmaceutica for delivery of formulation (October 2010, recognized as revenue during the third quarter of 2010);
· Receipt of a $2.5 million development milestone payment pursuant to the agreement with Merck (October 2010, recognized as revenue during the fourth quarter of 2010);
· Availability and re-launch of Glumetza 500mg tablets (January 2011);
· Achievement of $3.0 million Glumetza sales milestone payment from Santarus, Inc. to be paid in March 2011 (January 2011);
· US FDA approval of Gralise (gabapentin) once-daily tablets for treatment of post-herpetic neuralgia (January 2011);
· Results of the Phase 1 trial of twice-daily formulation of DM-1992 in Parkinson’s patients (February 2011);
· Receipt of a $48.0 million milestone payment from Abbott Products on FDA approval of Gralise (February 2011);
· Completion of enrollment in Breeze 3, our pivotal Phase 3 trial evaluating Serada for menopausal hot flashes (March 2011).
Depomed Fourth Quarter and Full-Year 2010 Financial Highlights
Total revenue for the fourth quarter of 2010 was $20.9 million compared to $13.2 million in the fourth quarter of 2009. The increase in revenue in the fourth quarter of 2010 was the result of recognition of the $2.5 million Merck milestone, an increase in Glumetza product sales and revenues related to our collaborative arrangements with Janssen and Covidien.
Total revenue for the year-ended December 31, 2010 was $80.8 million compared to $57.7 million for the year-ended December 31, 2009. The increase in revenue in 2010 was the result of increases in Glumetza product sales and revenues related to our collaborative arrangements with Abbott Products, Janssen and Covidien.
--------------------------------------------------------------------------------
Glumetza product sales were $11.5 million and $45.5 million for the fourth quarter and year-ended December 31, 2010, as compared to $9.8 million and $34.6 million for the corresponding periods in 2009.
Operating expenses were $18.5 million for the fourth quarter of 2010 and included $7.7 million in promotion fee expense related to the Company’s promotion agreement with Santarus, compared with operating expenses of $15.3 million for the fourth quarter of 2009, which included $6.6 million in promotion fee expense.
Operating expenses were $69.0 million for year ended December 31, 2010 and included $31.4 million in promotion fee expense, compared with operating expenses of $74.5 million for the year ended December 31, 2009, which included $23.6 million in promotion fee expense. The decrease in operating expenses for the year ended December 31, 2010 was primarily driven by the completion of the Phase 3 clinical trial for Gralise and completion of the first two Phase 3 clinical trials for Serada during 2009.
Net income during the fourth quarter of 2010 was $1.7 million, or $0.03 cents per share, compared to a net loss during the fourth quarter of 2009 of $3.6 million, or $0.07 cents per share.
Net income for the year ended December 31, 2010 was $3.9 million, or $0.07 cents per share, compared to a net loss during the year ended December 31, 2009 of $22.0 million, or $0.43 cents per share.
Cash, cash equivalents and marketable securities were $76.9 million as of December 31, 2010 compared to $81.8 million as of December 31, 2009. Cash, cash equivalents and marketable securities at December 31, 2010 does not include the $48.0 million milestone payment from Abbott Products that we received in February 2011.
Conference Call
Depomed will host a conference call today, Thursday, March 3, beginning at 5:00 p.m. ET, 2:00 p.m. PT to discuss its results. The conference call will be available via a live webcast on the investor relations section of Depomed’s website at http://www.depomed.com. Access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company’s website for three months.
About Depomed
Depomed, Inc. is a specialty pharmaceutical company with one approved product on the market and has developed another approved product. Gralise TM (gabapentin) is a once-daily treatment approved in the United States for management of post-herpetic neuralgia (PHN). Glumetza® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and promoted by Santarus, Inc. in the United States. The company also has a robust pipeline including one in Phase 3 clinical development, and other product candidates in its early stage pipeline. Product candidate Serada® is in Phase 3 clinical development for menopausal hot flashes. Depomed formulates its products and product candidates with its proven, proprietary Acuform® drug delivery technology, which is designed to improve existing oral medications, allowing for controlled release of medications to the upper gastrointestinal tract when dosed with food. Additional information about Depomed may be found on its website, http://www.depomed.com.
I may be very much in the minority with this, but thanks for taking the time to listen to the little people.... :)
I used to work for an office equipment dealer that was the "Official Office Equipment Dealer" of Pocono Raceway.
We had executive parking passes, concierge suite tickets, garage passes, hot pit passes, full bar and buffet during the race.....
But the infield is more fun!
Small suggestion:
Move the new order of standings to the left of the old order of standings. Might read better.
Wow Red, do you look like Trump too????? Comb over and all?
Abbott said they would honor the agreement. They however do not agree with Depomed regarding what is in the agreement. To me nothing was "not in dispute".
So my point is, there probably was no doubt regarding the payment to many, but that did not make the payment an absolutely done deal. Depomed had no doubts regarding Abbott's responsibilities to launch the drug, but that didn't launch it did it?
So having said that, the company was paid $48 million and as of my post had lost $25 million in market cap. That is surprising to me.
Hope I clearified my point.
I'm very surprised by the downward pressure with DEPO. A company gets paid $48 million and loses $25 million in market cap? All this is happening 100 shares at a time as probably 75% of the trades I've seen have been for 100 shares.
Should be a whole lot more scoring this week, with all the big names on top of the board.
the engines are done after the race anyway
First one I remember doing a burnout was senior. After he won the Daytona 500.
DEPO
Opened up this morning. $48 Million payment from Abbott is in. It has been six weeks since dispute, during the cc we were told between 3 to 8 weeks for mediation. So that time line is running out.
If my math is right 4.00 x's 75000 = 350,000 not 300,000 LOL...Glad we went to different schools 5 trillion shares and counting here...I'm the new CEO too
How about the fact that the guys name is GOATS..... too funny!
Really, that's the type of math that comes from home schooling, in West Virginia where students are sleepin wit da teach.
of 40870
DEPO
Depomed has added a news release to its Investor Relations website.
Title: Depomed Announces Receipt of a $48 million Milestone Payment for the Approval of GRALISE(TM)
Date(s): 28-Feb-2011 8:00 AM
For a complete listing of our news releases, please click here
Menlo Park, Calif., February 28, 2011 - Depomed, Inc. (NASDAQ: DEPO) today announced that it has received a $48 million milestone payment from Abbott Products, Inc., for the U.S. Food and Drug Administration's approval of GRALISE(TM) (gabapentin) Tablets for once-daily treatment of post-herpetic neuralgia (PHN), which is pain following healing of the rash associated with shingles.
DEPO
Depomed has added a news release to its Investor Relations website.
Title: Depomed Announces Receipt of a $48 million Milestone Payment for the Approval of GRALISE(TM)
Date(s): 28-Feb-2011 8:00 AM
For a complete listing of our news releases, please click here
Menlo Park, Calif., February 28, 2011 - Depomed, Inc. (NASDAQ: DEPO) today announced that it has received a $48 million milestone payment from Abbott Products, Inc., for the U.S. Food and Drug Administration's approval of GRALISE(TM) (gabapentin) Tablets for once-daily treatment of post-herpetic neuralgia (PHN), which is pain following healing of the rash associated with shingles.
Does that mean I was racin after the misses said no (actually NO!) last night?
My Sprint picks came in 1,2, 3 in Nationwide. How about a bonus point????/ ;)
OT:
My opinion is a simple one. The FDA behaves exactly as I would expect it to..... Like a government agency.
I don't think the best and the brightest go to work in any form of government as a general rule, so that leaves us with people who spend their day playing cya. The mentality of those that go to work for governement agencies is not that of a go getter, it seems always the attitude is why do today what you can put off until tomorrow.
Just an example, I overpaid sales tax in Pennsylvania on a vehicle purchase by $300. I sent in the paperwork on October 1, 2010, just got the check this week. 4 1/2 months to send out a refund, why? Because there is no hurry, no reward for excellence no punishment for laziness.
And that people, is my opinion of the FDA, no reward for excellence no punishment for laziness.
Sorry, I couldn't resist....
Probably why I got my face slapped as a child.......and a young man......and now an old man.